Eyenovia Inc
Company Overview
Eyenovia, Inc. is a clinical-stage ophthalmic biopharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems. The company is developing its proprietary Optejet dispensing technology to deliver micro-doses of medications to the eye. Their lead product candidate is MydCombi, which combines tropicamide and phenylephrine for mydriasis (pupil dilation).
The company's pipeline includes treatments for progressive myopia, presbyopia, and acute migraine. Eyenovia's innovative approach aims to improve the current standard of care in ophthalmic therapeutics by providing more precise dosing and enhanced delivery methods.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1625.0 | $7.94m | - | $602109.0 | 0.00% | 7.59% |
| June 30, 2024 | $22625.0 | $12.38m | - | $674001.0 | 0.00% | 5.44% |
| March 31, 2024 | $4993.0 | $10.95m | - | $678658.0 | 0.00% | 6.20% |
Company Impact
Help us evaluate Eyenovia Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.